Biomarker Data from KATHERINE: A Phase III Study of Adjuvant Trastuzumab Emtansine versus Trastuzumab in Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer

Study

Study ID	Alternative Stable ID	Type
EGAS00001006229		Other

Study Description

Study Datasets 2 datasets.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD00001008785	Clinical data for KATHERINE: Clinical data include Treatment Arm, Invasive Disease Free Survival (IDFS), Clinical Stage at Presentation, Hormone Receptor Status, Preoperative HER2 Directed Therapy, Pathological Node. Clinical data for KATHERINE: Clinical data include Treatment Arm, Invasive Disease Free Survival (IDFS), Clinical Stage at Presentation, Hormone Receptor Status, Preoperative HER2 Directed Therapy, Pathological Node.		1059
EGAD00001008786	Biomarker data for KATHERINE: Biomarker data include RNA-seq time point, Percent of tumor content, PAM50 subtypes, normalized gene expression of ERBB2, CD8 and CD274, normalized immune signature expression. Biomarker data for KATHERINE: Biomarker data include RNA-seq time point, Percent of tumor content, PAM50 subtypes, normalized gene expression of ERBB2, CD8 and CD274, normalized immune signature expression.		1059

Who archives the data?

Publications

Citations

Retrieving...